DexCom Valuation

Is DXCM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DXCM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DXCM ($139.48) is trading above our estimate of fair value ($129.1)

Significantly Below Fair Value: DXCM is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for DXCM?

Other financial metrics that can be useful for relative valuation.

DXCM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.8x
Enterprise Value/EBITDA68.4x
PEG Ratio4.9x

Price to Earnings Ratio vs Peers

How does DXCM's PE Ratio compare to its peers?

The above table shows the PE ratio for DXCM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39x
EW Edwards Lifesciences
40.8x9.0%US$57.3b
IDXX IDEXX Laboratories
53.1x9.9%US$44.8b
GEHC GE HealthCare Technologies
29.6x14.8%US$41.1b
RMD ResMed
32.4x13.6%US$28.8b
DXCM DexCom
99.3x20.3%US$53.8b

Price-To-Earnings vs Peers: DXCM is expensive based on its Price-To-Earnings Ratio (99.3x) compared to the peer average (39x).


Price to Earnings Ratio vs Industry

How does DXCM's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: DXCM is expensive based on its Price-To-Earnings Ratio (99.3x) compared to the US Medical Equipment industry average (40.6x).


Price to Earnings Ratio vs Fair Ratio

What is DXCM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DXCM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio99.3x
Fair PE Ratio52.3x

Price-To-Earnings vs Fair Ratio: DXCM is expensive based on its Price-To-Earnings Ratio (99.3x) compared to the estimated Fair Price-To-Earnings Ratio (52.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DXCM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$139.48
US$147.20
+5.5%
9.0%US$170.00US$105.00n/a23
Mar ’25US$121.74
US$146.39
+20.3%
8.8%US$170.00US$105.00n/a22
Feb ’25US$122.60
US$142.29
+16.1%
10.2%US$170.00US$105.00n/a20
Jan ’25US$124.09
US$133.51
+7.6%
11.1%US$161.00US$105.00n/a22
Dec ’24US$116.62
US$125.37
+7.5%
11.4%US$155.00US$101.00n/a22
Nov ’24US$94.13
US$125.98
+33.8%
11.8%US$155.00US$101.00n/a22
Oct ’24US$93.30
US$142.12
+52.3%
12.2%US$160.00US$92.00n/a21
Sep ’24US$101.90
US$146.55
+43.8%
10.7%US$175.00US$92.00n/a21
Aug ’24US$122.00
US$147.09
+20.6%
10.6%US$175.00US$92.00n/a21
Jul ’24US$128.51
US$139.42
+8.5%
10.2%US$152.00US$92.00n/a20
Jun ’24US$119.58
US$138.27
+15.6%
10.0%US$150.00US$92.00n/a20
May ’24US$118.44
US$137.91
+16.4%
10.2%US$150.00US$92.00n/a20
Apr ’24US$116.18
US$130.81
+12.6%
10.4%US$150.00US$92.00n/a20
Mar ’24US$110.76
US$129.69
+17.1%
10.2%US$150.00US$92.00US$121.7419
Feb ’24US$107.71
US$127.00
+17.9%
11.5%US$150.00US$92.00US$122.6018
Jan ’24US$113.24
US$126.94
+12.1%
11.9%US$150.00US$92.00US$124.0917
Dec ’23US$118.03
US$121.12
+2.6%
9.4%US$140.00US$92.00US$116.6217
Nov ’23US$119.04
US$121.12
+1.7%
9.4%US$140.00US$92.00US$94.1317
Oct ’23US$80.54
US$98.53
+22.3%
9.2%US$112.00US$81.00US$93.3015
Sep ’23US$83.08
US$97.81
+17.7%
9.4%US$112.00US$81.00US$101.9016
Aug ’23US$83.83
US$98.24
+17.2%
9.3%US$112.00US$81.00US$122.0017
Jul ’23US$77.63
US$120.89
+55.7%
16.9%US$150.00US$81.00US$128.5116
Jun ’23US$70.96
US$131.78
+85.7%
12.7%US$150.00US$78.75US$119.5817
May ’23US$102.15
US$134.53
+31.7%
13.2%US$157.50US$78.75US$118.4418
Apr ’23US$132.89
US$141.19
+6.2%
13.4%US$181.25US$78.75US$116.1820
Mar ’23US$102.10
US$139.94
+37.1%
13.6%US$181.25US$78.75US$110.7620

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.